Cargando…
A covalent PIN1 inhibitor selectively targets cancer cells by a dual mechanism of action
The prolyl isomerase PIN1, a critical modifier of multiple signalling pathways, is overexpressed in the majority of cancers and its activity strongly contributes to tumour initiation and progression. Inactivation of PIN1 function conversely curbs tumour growth and cancer stem cell expansion, restore...
Autores principales: | Campaner, Elena, Rustighi, Alessandra, Zannini, Alessandro, Cristiani, Alberto, Piazza, Silvano, Ciani, Yari, Kalid, Ori, Golan, Gali, Baloglu, Erkan, Shacham, Sharon, Valsasina, Barbara, Cucchi, Ulisse, Pippione, Agnese Chiara, Lolli, Marco Lucio, Giabbai, Barbara, Storici, Paola, Carloni, Paolo, Rossetti, Giulia, Benvenuti, Federica, Bello, Ezia, D'Incalci, Maurizio, Cappuzzello, Elisa, Rosato, Antonio, Del Sal, Giannino |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5472749/ https://www.ncbi.nlm.nih.gov/pubmed/28598431 http://dx.doi.org/10.1038/ncomms15772 |
Ejemplares similares
-
Oncogenic Hijacking of the PIN1 Signaling Network
por: Zannini, Alessandro, et al.
Publicado: (2019) -
Mutant p53 tunes the NRF2-dependent antioxidant response to support survival of cancer cells
por: Lisek, Kamil, et al.
Publicado: (2018) -
Immunohistochemical Characterization of a Renal Nephroblastoma in a Trp53-mutant and Prolyl Isomerase 1-deficient Mouse
por: Castiglioni, Vittoria, et al.
Publicado: (2013) -
MDP, a database linking drug response data to genomic information, identifies dasatinib and statins as a combinatorial strategy to inhibit YAP/TAZ in cancer cells
por: Taccioli, Cristian, et al.
Publicado: (2015) -
Breast Cancer Organoids Model Patient-Specific Response to Drug Treatment
por: Campaner, Elena, et al.
Publicado: (2020)